Dr. Adam Blomberg, Sheridan’s National Education Director, Anesthesiology Division, is a strong proponent of putting patients at the center of the entire perioperative period rather than just during preoperative testing. That’s the focus of a new program, TEMPO, that Sheridan has just begun to roll out formally at two partner facilities.
TEMPO evolved from Sheridan’s proprietary ClearPATh preadmission testing (PAT) framework, which significantly streamlined the PAT process by increasing efficiency and freeing up other operating room (OR) resources. This framework has helped Sheridan anesthesiologists reduce or eliminate unnecessary testing, consultations and preoperative visits and given them the tools to coordinate all the aspects of patient care they touch. ClearPATh has made PAT patient-centric rather than a cookie cutter testing approach. It has also shortened wait times and reduced same-day cancellations – a win-win-win for hospitals, physicians and patients.
For example, postoperative nausea is a common patient complaint. The TEMPO framework gives Sheridan anesthesiologists streamlined, readily accessible guidelines for postop nausea management as well as other aspects of postoperative pain management, including ERAS (enhanced recovery after surgery) programs. Sheridan is also preparing to pilot preoperative pharmacogenetic testing next year that will help anesthesiologists tailor medications based on patients’ genetic data. This will not only minimize negative drug reactions but also help identify patients with a predisposition to narcotic addiction. For these patients, Sheridan anesthesiologists can find pathways for treatment using no or limited opioids during the perioperative period.